Key Takeaways
Morgan Stanley initiates coverage on BridgeBio Pharma (BBIO) with an “Overweight” rating. Price target announced at $96.00 USD.Morgan Stan
BBIO’s Analyst Rating: Morgan Stanley Initiates Coverage with Overweight
Jan 6, 2026
![i’m-nervous,-too!-[part-2]](https://10xwealthreport.com/wp-content/uploads/2026/03/177042-im-nervous-too-part-2-1568x784.jpg)
